DE69535047D1 - L-Nukleoside zur Behandlung des Hepatitis-B- und Epstein-Bar-Virus - Google Patents

L-Nukleoside zur Behandlung des Hepatitis-B- und Epstein-Bar-Virus

Info

Publication number
DE69535047D1
DE69535047D1 DE69535047T DE69535047T DE69535047D1 DE 69535047 D1 DE69535047 D1 DE 69535047D1 DE 69535047 T DE69535047 T DE 69535047T DE 69535047 T DE69535047 T DE 69535047T DE 69535047 D1 DE69535047 D1 DE 69535047D1
Authority
DE
Germany
Prior art keywords
fluoro
beta
treatment
arabinofuranosyl
ebv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69535047T
Other languages
English (en)
Other versions
DE69535047T2 (de
Inventor
Chung K Chu
Yung-Chi Cheng
Balakrishna S Pai
Gang-Qing Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
University of Georgia Research Foundation Inc UGARF
Original Assignee
Yale University
University of Georgia Research Foundation Inc UGARF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22695792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69535047(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yale University, University of Georgia Research Foundation Inc UGARF filed Critical Yale University
Publication of DE69535047D1 publication Critical patent/DE69535047D1/de
Application granted granted Critical
Publication of DE69535047T2 publication Critical patent/DE69535047T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
DE69535047T 1994-01-28 1995-01-30 L-Nukleoside zur Behandlung von Hepatitis-B-Virus und Epstein-Barr Virus Expired - Lifetime DE69535047T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US189070 1994-01-28
US08/189,070 US5587362A (en) 1994-01-28 1994-01-28 L-nucleosides

Publications (2)

Publication Number Publication Date
DE69535047D1 true DE69535047D1 (de) 2006-07-20
DE69535047T2 DE69535047T2 (de) 2006-12-07

Family

ID=22695792

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69535047T Expired - Lifetime DE69535047T2 (de) 1994-01-28 1995-01-30 L-Nukleoside zur Behandlung von Hepatitis-B-Virus und Epstein-Barr Virus
DE69530192T Expired - Lifetime DE69530192T2 (de) 1994-01-28 1995-01-30 L-nukleoside zur behandlung des hepatitis-b- und epstein-bar-virus

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69530192T Expired - Lifetime DE69530192T2 (de) 1994-01-28 1995-01-30 L-nukleoside zur behandlung des hepatitis-b- und epstein-bar-virus

Country Status (23)

Country Link
US (3) US5587362A (de)
EP (2) EP0748330B1 (de)
JP (1) JP3899440B2 (de)
KR (1) KR100321209B1 (de)
CN (1) CN1043769C (de)
AT (2) ATE236186T1 (de)
AU (1) AU710262B2 (de)
BG (1) BG62571B1 (de)
BR (1) BRPI9506596B8 (de)
CA (1) CA2182273C (de)
CZ (1) CZ292574B6 (de)
DE (2) DE69535047T2 (de)
DK (2) DK0748330T3 (de)
ES (2) ES2194902T3 (de)
FI (4) FI117475B (de)
HK (1) HK1014716A1 (de)
HU (1) HU228135B1 (de)
NO (1) NO306408B1 (de)
NZ (2) NZ330137A (de)
PT (2) PT1283211E (de)
RO (1) RO116623B1 (de)
SK (1) SK285191B6 (de)
WO (1) WO1995020595A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
US6025335A (en) * 1995-09-21 2000-02-15 Lipitek International, Inc. L-Nucleoside Dimer Compounds and therapeutic uses
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
EP1302474A1 (de) * 1996-10-16 2003-04-16 Ribapharm, Inc. Monzyklische L-Nukleoside, deren Analoga und Verwendung
CA2266889A1 (en) * 1996-10-16 1998-04-23 Guangyi Wang Purine l-nucleosides, analogs and uses thereof
EP1072607A3 (de) * 1996-10-16 2001-09-12 ICN Pharmaceuticals, Inc. Purin-L-Nukleoside, deren Analoga und Verwendungen
DE69721339T2 (de) 1996-10-16 2004-01-22 Ribapharm, Inc., Costa Mesa Monozyklische l-nukleoside, analoga und ihre anwendungen
US6509320B1 (en) * 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
TW434252B (en) * 1997-07-23 2001-05-16 Univ Georgia Res Found Process for the preparation of 2'-fluoro-5-methyl-β-L-arabino-furanosyluridine
GB9716567D0 (en) * 1997-08-05 1997-10-08 Pfizer Process
US6090602A (en) 1998-02-18 2000-07-18 Promelas Research Corporation Levo-monosaccharide in a nucleoside analog for use as an anti-retroviral agent
IL138037A0 (en) * 1998-02-25 2001-10-31 Univ Emory 2'-fluoronucleosides
KR100449618B1 (ko) * 1998-03-27 2004-11-16 부광약품 주식회사 2'-플루오로-5-메틸-β-L-아라비노푸라노실유리딘의 제조방법
AU3751299A (en) * 1998-04-20 1999-11-08 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
AU5475799A (en) * 1998-08-10 2000-03-06 Centre National De La Recherche Scientifique Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis
EP1380303B1 (de) 1998-11-02 2008-09-17 Gilead Sciences, Inc. Kombinationstherapie zur Behandlung von Hepatitis B Infektionen
US6407077B1 (en) 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
AU777869B2 (en) * 1999-09-24 2004-11-04 Shire Canada Inc. Method for the treatment or prevention of viral infection using nucleoside analogues
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
IL151981A0 (en) * 2000-03-29 2003-04-10 Univ Georgetown Method of treating hepatitis delta viral infection
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
CN1315862C (zh) 2000-05-26 2007-05-16 艾登尼科斯（开曼）有限公司 处理黄病毒和瘟病毒的方法和组合物
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
WO2002006296A1 (fr) * 2000-07-19 2002-01-24 Mitsui Chemicals, Inc. Procedes de preparation de derives de compose d'acide nucleique 2,2'-anhydro
CN1646141B (zh) * 2000-10-18 2014-06-25 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
DK1574512T3 (da) * 2001-03-01 2008-03-03 Abbott Lab Polymorfe og andre krystallinske former af cis-FTC
NZ528575A (en) * 2001-03-30 2006-04-28 Bukwang Pharmaceutical Co Process for the preparation of 2'-halo-beta-L-arabinofuranosyl nucleosides
GB0112617D0 (en) * 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
JP2005503358A (ja) 2001-06-22 2005-02-03 フアーマセツト・リミテツド β−２’−または３’−ハロヌクレオシド
KR100487992B1 (ko) * 2001-10-25 2005-05-09 부광약품 주식회사 2'-플루오로-5-메틸-β-엘-아라비노푸라노실유리딘의 황유도체
JP4651942B2 (ja) * 2001-12-20 2011-03-16 フアーマセツト・インコーポレイテッド Ｅｂｖ及びｋｈｓｖ感染並びにそれに伴う異常細胞増殖の治療
SE521676C2 (sv) * 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
US7456155B2 (en) 2002-06-28 2008-11-25 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TWI244393B (en) * 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
PT1572095E (pt) * 2002-09-13 2015-10-13 Novartis Ag Β-l-2'-desoxinucleósidos para tratamento de estirpes resistentes de vhb
EP1576138B1 (de) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nukleoside in kombination mit interferon und flaviviridae-mutation
KR20050109918A (ko) 2002-12-12 2005-11-22 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드의 제조 방법
WO2004084453A2 (en) * 2003-03-20 2004-09-30 Microbiologica Quimica E Farmaceutica Ltd. METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
ES2726998T3 (es) 2003-05-30 2019-10-11 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
CN101044151B (zh) * 2004-08-23 2011-01-19 弗·哈夫曼-拉罗切有限公司 抗病毒的4＇-叠氮基-核苷
JP2006265156A (ja) * 2005-03-23 2006-10-05 Ajinomoto Co Inc ２−デオキシ−ｌ−リボフラノシルクロリド化合物の製造方法
WO2006133092A1 (en) * 2005-06-07 2006-12-14 Yale University Methods of treating cancer and other conditions or disease states using lfmau and ldt
WO2007067364A2 (en) 2005-12-02 2007-06-14 Yale University Methods of treating cancer and other conditions or disease states using l-cytosine nucleoside analogs
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
EP1976382B1 (de) 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Verfahren zur herstellung eines synthetischen zwischenprodukts für die herstellung von verzweigten nukleosiden
US8895531B2 (en) * 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
AU2007306405A1 (en) * 2006-10-10 2008-04-17 Medivir Ab HCV nucleoside inhibitor
JP5550234B2 (ja) 2006-12-08 2014-07-16 株式会社エーピーアイ コーポレーション フラノース誘導体の製造方法
JP5326173B2 (ja) * 2007-09-10 2013-10-30 栄一 児玉 エプスタイン・バールウイルス関連疾患に対する薬剤およびそのスクリーニング法
US20090274686A1 (en) * 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
EA039123B1 (ru) * 2014-12-15 2021-12-08 Эмори Юниверсити Фосфорамидаты для лечения вируса гепатита в
JP6735751B2 (ja) * 2014-12-15 2020-08-05 エモリー ユニバーシティー Ｂ型肝炎ウイルスの治療のためのホスホルアミデート
SG11201811316YA (en) 2016-06-24 2019-01-30 Univ Emory Phosphoramidates for the treatment of hepatitis b virus
CN109467583A (zh) * 2018-11-17 2019-03-15 扬州工业职业技术学院 一种克拉夫定的绿色合成工艺

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3116268A (en) * 1955-12-21 1963-12-31 Du Pont Polyphosphonamide polymers and copolymers
US3116266A (en) * 1960-06-17 1963-12-31 Minnesota Mining & Mfg Scorch resistant, thermally curable polymeric compositions, and their curing
US3553192A (en) * 1968-07-15 1971-01-05 Robugen Gmbh Substituted (2'-deoxyribosyl) uracil compounds, compositions containing same and process of making and using same
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
US4666892A (en) * 1984-03-06 1987-05-19 Sloan-Kettering Memorial Cancer Center Method and composition for hepatitis treatment with pyrimidine nucleoside compounds
JPH07116042B2 (ja) * 1985-05-15 1995-12-13 ザ ウエルカム フアウンデ−シヨン リミテツド ヌクレオシド化合物
AU570853B2 (en) * 1985-08-26 1988-03-24 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Inhibition of infectivity and cytopathic effect of htlv-111/ lav by purine bases
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
GB2181128A (en) * 1985-09-17 1987-04-15 Wellcome Found 3'-azidonucleosides
IN164556B (de) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5446029A (en) * 1986-07-04 1995-08-29 Medivir Ab Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides
GB8617861D0 (en) * 1986-07-22 1986-08-28 Ciba Geigy Ag Flame retardant compositions
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
US5215971A (en) * 1986-12-19 1993-06-01 Medivir Ab Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides
IL85778A0 (en) * 1987-03-20 1988-09-30 Bristol Myers Co Production of 2',3'-dideoxynucleosides and certain such novel compounds
AU613026B2 (en) * 1987-03-24 1991-07-25 Nycomed As 2',3' dideoxyribofuranoxide derivatives
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
US5215970A (en) * 1987-04-16 1993-06-01 Medivir Ab Nucleosides and nucleotide analogues, pharmaceutical composition and processes for the preparation of the compounds
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds
US5246924A (en) * 1987-09-03 1993-09-21 Sloan-Kettering Institute For Cancer Research Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil
IL87646A (en) * 1987-09-03 1994-07-31 Sloan Kettering Inst Cancer Preparation for the treatment of hepatitis virus containing 1 -) 2 '- Deoxy - 2' - Fluoro - Beta - B - D - Arabino - Furanozil (- 5 - Orcil
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
JP2788084B2 (ja) * 1988-12-19 1998-08-20 ザ ウエルカム フアウンデーシヨン リミテツド 抗ウイルス化合物
ES2196004T3 (es) * 1989-02-08 2003-12-16 Iaf Biochem Int Procedimiento para preparar 1,3-oxatiolanos sustituidos con propiedades antivirales.
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
SE9003151D0 (sv) * 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
IT1246983B (it) * 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
WO1992010496A1 (en) * 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
CA2105486C (en) * 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
EP0586560A1 (de) * 1991-05-23 1994-03-16 Schering Corporation Neue benzopyrido-piperidyliden verbindungen, zusammensetzungen, verfahren zur herstellung und verwendung
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US5432165A (en) * 1992-04-06 1995-07-11 Oclassen Pharmaceuticals, Inc. Methods for the treatment of infection caused by Hepatitis B virus (HBV)
FR2698325B1 (fr) * 1992-11-20 1995-01-13 Renault Dispositif de commande de débrayage à l'arrêt de transmission automatique.
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
US5439893A (en) * 1993-05-26 1995-08-08 University Of Montana Methods for the treatment and prevention of diarrhea
JPH09504785A (ja) * 1993-09-10 1997-05-13 エモリー、ユニバーシティー 抗ｂ型肝炎ウイルス活性を有するヌクレオシド
FR2709754B1 (fr) * 1993-09-10 1995-12-01 Centre Nat Rech Scient Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale.
AU1596495A (en) * 1993-12-30 1995-07-17 Genta Incorporated Improved process for the purification of oligomers
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides

Also Published As

Publication number Publication date
FI962986A0 (fi) 1996-07-26
BG62571B1 (bg) 2000-02-29
CZ211496A3 (cs) 1998-09-16
RO116623B1 (ro) 2001-04-30
US5587362A (en) 1996-12-24
NO306408B1 (no) 1999-11-01
CN1143966A (zh) 1997-02-26
BR9506596A (pt) 1997-09-09
FI962986A (fi) 1996-07-26
EP0748330A1 (de) 1996-12-18
CA2182273A1 (en) 1995-08-03
DE69530192T2 (de) 2004-01-08
FI118954B (fi) 2008-05-30
FI119416B (fi) 2008-11-14
CA2182273C (en) 2006-07-11
PT1283211E (pt) 2006-09-29
WO1995020595A1 (en) 1995-08-03
HUT75514A (en) 1997-05-28
KR100321209B1 (ko) 2002-10-04
US5567688A (en) 1996-10-22
NO963138L (no) 1996-09-26
FI20051033A (fi) 2005-10-13
PT748330E (pt) 2003-08-29
ES2266402T3 (es) 2007-03-01
BG100792A (bg) 1997-03-31
HU228135B1 (en) 2012-12-28
HK1014716A1 (en) 1999-09-30
ATE328889T1 (de) 2006-06-15
FI20070005A (fi) 2007-01-03
AU1737695A (en) 1995-08-15
EP1283211A3 (de) 2003-02-19
FI20080432A (fi) 2008-07-08
BR9506596B1 (pt) 2010-10-05
FI121846B (fi) 2011-05-13
FI117475B (fi) 2006-10-31
DK1283211T3 (da) 2006-10-09
EP0748330B1 (de) 2003-04-02
EP0748330A4 (de) 1997-03-19
DE69530192D1 (de) 2003-05-08
JP3899440B2 (ja) 2007-03-28
CN1043769C (zh) 1999-06-23
SK285191B6 (sk) 2006-08-03
US5565438A (en) 1996-10-15
EP1283211A2 (de) 2003-02-12
JPH09508394A (ja) 1997-08-26
CZ292574B6 (cs) 2003-10-15
NO963138D0 (no) 1996-07-26
DK0748330T3 (da) 2003-07-28
BRPI9506596B8 (pt) 2016-05-24
AU710262B2 (en) 1999-09-16
ES2194902T3 (es) 2003-12-01
DE69535047T2 (de) 2006-12-07
ATE236186T1 (de) 2003-04-15
HU9601774D0 (en) 1996-09-30
SK92696A3 (en) 1997-08-06
NZ281058A (en) 1998-06-26
NZ330137A (en) 2000-08-25
EP1283211B1 (de) 2006-06-07

Similar Documents

Publication Publication Date Title
DE69535047D1 (de) L-Nukleoside zur Behandlung des Hepatitis-B- und Epstein-Bar-Virus
ATE165004T1 (de) Ematiomerenreine beta-d-dioxolane nucleoside mit selektiver antihepatitis b-virus wirkung
GB8920534D0 (en) Antiviral compounds
ATE314077T1 (de) 5-fluoro-2',3'-ungesättigte pyrimidinnucleoside
FI20001231A (fi) 2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina
DK615788A (da) Nucleosidforbindelser til anvendelse mod virale infektioner
ES2105923A1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
MX9603029A (es) Nucleosidos-l para el tratamiento del virus-b de hepatitis y el virus de epstein-barr.
ES2078380T3 (es) Oligofosfatos de accion antiviral.
RU96117323A (ru) L-нуклеозиды для лечения заболеваний, вызванных вирусом гепатита b и вирусом эпштейна - барра
RU98103770A (ru) 2-амино-9-(3-гидроксиметил-4-алкоксикарбонилоксибут-1-ил)пурина и фармацевтическая композиция, содержащая его
TW217986B (en) Compositions for the treatment of infection and disease caused by HBV
JPS5673022A (en) Antiviral agent

Legal Events

Date Code Title Description
8364 No opposition during term of opposition